Coeptis Therapeutics, Inc.

NASDAQ:COEP

Biotechnology

Healthcare
$14.64 +4.68%

+$0.73 today

Market cap
$57.63M
Beta
-0.43
P/E (TTM)
-8.3
EPS (TTM)
-$1.97
52W Low $6.80High $21.41

Volume 0.18M

Average 0.05M

COEP Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Coeptis Therapeutics, Inc.NASDAQ: COEP

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit grows, but more slowly than its trailing trend

Q1 FY2026 gross profit of $68.62K rose 287.3% year over year, behind the +6860.8% change in trailing-twelve-month gross profit. Sequentially, it fell 91.6% from the prior quarter.

Context

  • Gross profit amounted to 86.7% of revenue in FY2025.
  • Gross profit increased in 1 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +287.3% toward the trailing-twelve-month pace of +6860.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$68.62K-91.6% QoQ
Last fiscal yearDec 2025
$1.18M— YoY
LTMMar 2026
$1.23M+6860.8% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+287.3%——
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

USD · from the income statement

Latest · FY2025
1.18M USD
Year-over-year change
—
4-year CAGR
+99.3%

Gross Profit vs competitors

How COEP compares with its peers on the latest reported figures

  • COEP's LTM Mar 2026 gross profit of $1.23M is the 3rd highest of the 9 companies compared; the peer median is -$39.5K.
  • Its year-over-year change of +6860.8% is the 2nd highest of 8, against a peer median of -100.3%.
  • Gross profit amounts to 87.2% of revenue for COEP, versus a peer median of 97.9%.
COEP Competitors Peer median
Gross Profit for COEP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$145.11M +6.2%-2.6%96.0%
CUECue Biopharma, Inc.LTM Mar 2026$32.65M +308.6%+180.5%99.8%
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$1.23M +6860.8%—87.2%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$851K +21375.0%—37.1%
TELOTelomir Pharmaceuticals, Inc. Common StockLTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026-$79K -100.3%——
OSTXOS Therapies IncorporatedLTM Mar 2026-$362.39K -17280.8%——
OTLKOutlook Therapeutics, Inc.LTM Mar 2026-$1.2M -4457.3%—360.9%
IPSCCentury Therapeutics, Inc.LTM Mar 2026-$29.86M -126.0%+164.4%—
Peer median (excluding COEP) -$39.5K-100.3%+164.4%97.9%

Competitors are the stored peer set for COEP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue75K0001.36M
Cost of Revenue0000180.63K
Gross Profit75K0001.18M
Gross Margin100.0%———86.7%
Research & Development020.89K6.67M2.33M1.28M
Selling, General & Admin14.12M34.18M13.82M6.72M11.95M
Operating Expenses14.12M34.2M21.49M10.05M14.23M
Depreciation & Amortization447.41K1M1.04M1.04M1.22M
EBITDA(12.81M)(36.35M)(20.12M)(9.38M)(10.41M)
EBITDA Margin-17086.3%———-763.9%
Operating Income(14.05M)(34.2M)(21.49M)(10.05M)(13.04M)
Operating Margin-18727.9%———-956.9%
Interest Income0000116.5K
Interest Expense187.13K218.41K107.69K396.12K642.38K
Other Income / Expenses596.65K(3.38M)224.59K(822.92K)766.31K
Income Before Tax(13.45M)(37.57M)(21.27M)(10.88M)(12.28M)
Pre-Tax Margin-17932.4%———-900.7%
Income Tax Expense00000
Net Income(13.45M)(37.57M)(21.27M)(10.68M)(11.92M)
Net Margin-17932.4%———-874.3%
EPS (Basic)(13.16)(2.87)(0.83)(5.65)(2.81)
EPS (Diluted)(13.16)(2.87)(0.83)(5.65)(2.81)
Weighted Avg Shares1.02M14.3M25.69M1.93M4.23M
Weighted Avg Shares (Diluted)1.02M14.3M25.69M1.93M4.23M

Coeptis Therapeutics, Inc.

NASDAQ:COEP

Intrinsic Alpha fair value

Locked

Current Price

$14.64

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.